As part JAMA‘s recent obesity-themed issue, one author outlined how he’s “reimagining” obesity in 2018. Catch up on MedPage Today’s coverage of this special issue, including the mortality benefits of bariatric surgery, bypass versus sleeve procedures, and cardiovascular post-op outcomes.
Both type 1 and type 2 diabetes carry major risks for pregnant women — both tied to outcomes such as stillbirths, emergency c-sections, and infant mortality. (Diabetologia)
FitBit is making a foray into the world of diabetes, forging partnerships with UnitedHealthcare — on a pilot type 2 diabetes management program — and Dexcom, on a new smartwatch glucose tracker. (Wareable)
In an analysis by the TEDDY team, 6 new non-HLA chromosomal regions were identified in youth at risk for type 1 diabetes. “We want to build a more precise profile of who will get this disease and when,” Jin-Xiong She, PhD, principal investigator of TEDDY’s Georgia/Florida site, said in a statement. (Journal of Autoimmunity)
President Trump’s annual physical revealed he has a BMI of 29.9 — putting him on the cusp of obesity. (MedPage Today)
Once thought of as a major anti-aging hormone, a new study found the effects of alpha-Klotho may in fact be attributed to an associated protein, fibroblast growth factor 23 (FGF-23). (FierceBiotech)
Daniel J. Drucker, MD, best known for his work in diabetes, was named the new editor-in-chief of the Endocrine Society’s journal, Endocrine Reviews.
The American Diabetes Association announced their new leadership team for 2018, including the elected team for 2019.
Researchers identified a new target — the protein STUB1 — that may help prevent blood clots from forming in patients with chronic kidney disease. The work “supports further studies probing its utility in risk stratification of CKD patients and exploring its role in other diseases with heightened risk of thrombosis,” study author Katya Ravid, DSc, said in a statement. (Journal of the American Society of Nephrology)